Leukapheresis Clinical Trials
31 recruitingProcedure
Phase 120Phase 29Early Phase 13Phase 31
Showing 1–20 of 31 trials
Recruiting
Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled175 locationsNCT06172296
Recruiting
Early Phase 1
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute16 enrolled1 locationNCT06435351
Recruiting
Phase 1
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute26 enrolled1 locationNCT06871410
Recruiting
Phase 1
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting
Phase 1
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 2
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726
Recruiting
Phase 1
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRecurrent Multiple Myeloma
Thomas Martin, MD30 enrolled1 locationNCT07340853
Recruiting
Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaHigh Grade B-Cell Non-Hodgkin's Lymphoma+1 more
City of Hope Medical Center15 enrolled1 locationNCT05801913
Recruiting
Phase 2
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Jennifer Crombie, MD35 enrolled2 locationsNCT05934448
Recruiting
Phase 2
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center56 enrolled1 locationNCT07042438
Recruiting
Phase 2
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma+5 more
Aseel Alsouqi24 enrolled3 locationsNCT05873712
Recruiting
Phase 1Phase 2
Stem Cell Transplantation in Crohn's Disease
Crohn Disease
Cedars-Sinai Medical Center15 enrolled1 locationNCT04224558
Recruiting
Phase 1Phase 2
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
Fred Hutchinson Cancer Center48 enrolled1 locationNCT06236139
Recruiting
Phase 1
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic27 enrolled1 locationNCT06191887
Recruiting
Phase 1
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Recurrent OsteosarcomaRefractory OsteosarcomaAdvanced Osteosarcoma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07227571
Recruiting
Early Phase 1
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center9 enrolled1 locationNCT05800405
Recruiting
Phase 1
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Adenocarcinoma
City of Hope Medical Center30 enrolled1 locationNCT07219147
Recruiting
Phase 2
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373
Recruiting
Phase 1Phase 2
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Fred Hutchinson Cancer Center33 enrolled1 locationNCT07098364
Recruiting
Phase 1
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Metastatic Malignant Solid Neoplasm
Fred Hutchinson Cancer Center24 enrolled1 locationNCT06043713